[Edaily Reporter Shin Ha-yeon ] HCT(072990), a company specializing in testing, certification, and calibration, announced on the 4th that it has appointed Kwon Yong-taek, an inside director, as co-CEO. This personnel decision is part of a management restructuring aimed at improving profitability and reorganizing the business structure in response to the rapidly changing market environment, while also strengthening organizational stability and laying the foundation for future growth. Co-CEO Kwon Yong-taek, a graduate of Hanyang University’s Department of Electronic Engineering and a former employee of Hyundai Electronics Industries, was a founding member who participated in the establishment of HCT in 2000. Since then, he has served as Head of the Calibration Business Division and Head of the Corporate Planning Office, and later as CEO of HNH Bio. The company explained that he has been recognized for his capabilities in organizational management, business strategy, and profit and loss management within the calibration business sector. Moving forward, HCT plans to accelerate the normalization of management and the strengthening of business competitiveness under the co-CEO system led by Kwon Yong-taek and Heo Bong-jae, with the aim of providing more stable services to customers and partners. Co-CEO Kwon Yong-taek stated, “Now is the most critical time to restore profitability and regain customer trust,” adding, “We will objectively reassess our business structure and lay the foundation for sustainable growth by improving cost efficiency and strengthening the competitiveness of our core businesses.” He added, “Together with our employees, we will do our utmost to quickly stabilize the organization and restore the trust of our customers and partners.”
With investment in artificial intelligence (AI) infrastructure surging, growth across the entire semiconductor value chain—from foundries to advanced packaging and testing—is accelerating.
Accordin…
Ahead of Shinsegae Co.,Ltd’s regular executive reshuffle, attention is focused on the composition of the management team that will support Chairman Jeong Yong-jin’s “responsible management.” This is b…
Korean pharmaceutical, biotech, and healthcare stocks showed sharply mixed movements on September 29 as company-specific news drove trading. AriBio Holdings plunged to its daily lower limit in after-h…